BMS signs $475m deal with Dragonfly Therapeutics for IL-12 programme

Bristol Myers Squibb, Dragonfly Therapeutics sign licensing deal for the latter’s IL-12 programme. (Credit: Rept0n1x/Wikipedia.org)